Cargando…

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data

BACKGROUND: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), its sustainability and effect on liver fibrosis ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Arai, Taeang, Atsukawa, Masanori, Tsubota, Akihito, Mikami, Shigeru, Ono, Hiroki, Kawano, Tadamichi, Yoshida, Yuji, Tanabe, Tomohide, Okubo, Tomomi, Hayama, Korenobu, Nakagawa-Iwashita, Ai, Itokawa, Norio, Kondo, Chisa, Kaneko, Keiko, Emoto, Naoya, Nagao, Mototsugu, Inagaki, Kyoko, Fukuda, Izumi, Sugihara, Hitoshi, Iwakiri, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989116/
https://www.ncbi.nlm.nih.gov/pubmed/33815743
http://dx.doi.org/10.1177/20420188211000243
_version_ 1783668897537327104
author Arai, Taeang
Atsukawa, Masanori
Tsubota, Akihito
Mikami, Shigeru
Ono, Hiroki
Kawano, Tadamichi
Yoshida, Yuji
Tanabe, Tomohide
Okubo, Tomomi
Hayama, Korenobu
Nakagawa-Iwashita, Ai
Itokawa, Norio
Kondo, Chisa
Kaneko, Keiko
Emoto, Naoya
Nagao, Mototsugu
Inagaki, Kyoko
Fukuda, Izumi
Sugihara, Hitoshi
Iwakiri, Katsuhiko
author_facet Arai, Taeang
Atsukawa, Masanori
Tsubota, Akihito
Mikami, Shigeru
Ono, Hiroki
Kawano, Tadamichi
Yoshida, Yuji
Tanabe, Tomohide
Okubo, Tomomi
Hayama, Korenobu
Nakagawa-Iwashita, Ai
Itokawa, Norio
Kondo, Chisa
Kaneko, Keiko
Emoto, Naoya
Nagao, Mototsugu
Inagaki, Kyoko
Fukuda, Izumi
Sugihara, Hitoshi
Iwakiri, Katsuhiko
author_sort Arai, Taeang
collection PubMed
description BACKGROUND: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), its sustainability and effect on liver fibrosis have remained unclear. The current study aimed to clarify the effects of 48-week SGLT2-I therapy on liver inflammation, fatty changes, and fibrosis in NAFLD patients with T2DM. METHODS: This study evaluated the effects of SGLT2-I on NAFLD, including liver fibrosis assessed via transient elastography, in 56 patients with NAFLD who received SGLT2-I for 48 weeks. Moreover, changes in each clinical parameter between patients receiving SGLT2-I (the SGLT2-I group) and those receiving other oral hypoglycemic agents (OHAs) (the non-SGLT2-I group) were compared, using 1:1 propensity score matching to adjust for baseline factors. RESULTS: The SGLT2-I group exhibited a significant decrease in controlled attenuation parameter (312 dB/m at baseline to 280 dB/m at week 48) and liver stiffness measurement (9.1–6.7 kPa) (p < 0.001 for both). After propensity score matching (44 patients each in the SGLT2-I and non-SGLT2-I groups), no significant difference in HbA1c decrease was observed between the two groups. However, compared with the non-SGLT2-I group, the SGLT2-I group showed a significant decrease in body weight (p < 0.001), alanine aminotransferase (p = 0.02), uric acid (p < 0.001), and Fibrosis-4 (FIB-4) index (p = 0.01) at week 48. The improvement in FIB-4 index, defined as a ⩾10% decline from baseline at week 48, was 56.8% (25/44) in the SGLT2-I group and 20.5% (9/44) in the non-SGLT2-I group (p < 0.001). CONCLUSION: SGLT2-Is improved not only glycemic control but also liver fatty infiltration and fibrosis in patients with NAFLD and T2DM, suggesting their possible superiority to other OHAs concerning these effects.
format Online
Article
Text
id pubmed-7989116
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-79891162021-04-02 Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data Arai, Taeang Atsukawa, Masanori Tsubota, Akihito Mikami, Shigeru Ono, Hiroki Kawano, Tadamichi Yoshida, Yuji Tanabe, Tomohide Okubo, Tomomi Hayama, Korenobu Nakagawa-Iwashita, Ai Itokawa, Norio Kondo, Chisa Kaneko, Keiko Emoto, Naoya Nagao, Mototsugu Inagaki, Kyoko Fukuda, Izumi Sugihara, Hitoshi Iwakiri, Katsuhiko Ther Adv Endocrinol Metab Original Research BACKGROUND: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), its sustainability and effect on liver fibrosis have remained unclear. The current study aimed to clarify the effects of 48-week SGLT2-I therapy on liver inflammation, fatty changes, and fibrosis in NAFLD patients with T2DM. METHODS: This study evaluated the effects of SGLT2-I on NAFLD, including liver fibrosis assessed via transient elastography, in 56 patients with NAFLD who received SGLT2-I for 48 weeks. Moreover, changes in each clinical parameter between patients receiving SGLT2-I (the SGLT2-I group) and those receiving other oral hypoglycemic agents (OHAs) (the non-SGLT2-I group) were compared, using 1:1 propensity score matching to adjust for baseline factors. RESULTS: The SGLT2-I group exhibited a significant decrease in controlled attenuation parameter (312 dB/m at baseline to 280 dB/m at week 48) and liver stiffness measurement (9.1–6.7 kPa) (p < 0.001 for both). After propensity score matching (44 patients each in the SGLT2-I and non-SGLT2-I groups), no significant difference in HbA1c decrease was observed between the two groups. However, compared with the non-SGLT2-I group, the SGLT2-I group showed a significant decrease in body weight (p < 0.001), alanine aminotransferase (p = 0.02), uric acid (p < 0.001), and Fibrosis-4 (FIB-4) index (p = 0.01) at week 48. The improvement in FIB-4 index, defined as a ⩾10% decline from baseline at week 48, was 56.8% (25/44) in the SGLT2-I group and 20.5% (9/44) in the non-SGLT2-I group (p < 0.001). CONCLUSION: SGLT2-Is improved not only glycemic control but also liver fatty infiltration and fibrosis in patients with NAFLD and T2DM, suggesting their possible superiority to other OHAs concerning these effects. SAGE Publications 2021-03-21 /pmc/articles/PMC7989116/ /pubmed/33815743 http://dx.doi.org/10.1177/20420188211000243 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Arai, Taeang
Atsukawa, Masanori
Tsubota, Akihito
Mikami, Shigeru
Ono, Hiroki
Kawano, Tadamichi
Yoshida, Yuji
Tanabe, Tomohide
Okubo, Tomomi
Hayama, Korenobu
Nakagawa-Iwashita, Ai
Itokawa, Norio
Kondo, Chisa
Kaneko, Keiko
Emoto, Naoya
Nagao, Mototsugu
Inagaki, Kyoko
Fukuda, Izumi
Sugihara, Hitoshi
Iwakiri, Katsuhiko
Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
title Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
title_full Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
title_fullStr Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
title_full_unstemmed Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
title_short Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
title_sort effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989116/
https://www.ncbi.nlm.nih.gov/pubmed/33815743
http://dx.doi.org/10.1177/20420188211000243
work_keys_str_mv AT araitaeang effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT atsukawamasanori effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT tsubotaakihito effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT mikamishigeru effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT onohiroki effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT kawanotadamichi effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT yoshidayuji effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT tanabetomohide effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT okubotomomi effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT hayamakorenobu effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT nakagawaiwashitaai effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT itokawanorio effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT kondochisa effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT kanekokeiko effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT emotonaoya effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT nagaomototsugu effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT inagakikyoko effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT fukudaizumi effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT sugiharahitoshi effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata
AT iwakirikatsuhiko effectofsodiumglucosecotransporter2inhibitorinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusapropensityscorematchedanalysisofrealworlddata